Therapeutic human papillomavirus vaccines: current clinical trials and future directions (Q56937332)

Europe PubMed Central

title

Therapeutic human papillomavirus vaccines: current clinical trials and future directions (English)

0 references

1 reference

Chien-Fu Hung

1

0 references

Barbara Ma

2

0 references

Archana Monie

3

0 references

Shaw-Wei Tsen

4

0 references

T-C Wu

Expert Opinion on Biological Therapy

5

0 references

language of work or name

English

0 references

publication date

April 2008

0 references

published in

0 references

volume

8

0 references

issue

4

0 references

page(s)

421-39

0 references

cites work

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Development of HPV Vaccines for HPV-associated Head and Neck Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Papillomaviruses and cancer: from basic studies to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Production of human papillomavirus type 16 E7 protein in Lactococcus lactis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Opportunities to improve the prevention and treatment of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Design and development of synthetic peptide vaccines: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Comparison of HPV DNA vaccines employing intracellular targeting strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancing immune responses using suicidal DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-Expressing sindbis virus replicon particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

IDO and tolerance to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Improving DNA vaccine potency via modification of professional antigen presenting cells.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Viral vectors for gene transfer into antigen presenting cells.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Experimental vaccine strategies for cancer immunotherapy

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074340

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

2 November 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.4.421

Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy

21 January 2018

1 reference

12 December 2020

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial

1 reference

12 December 2020

Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors

1 reference

12 December 2020

Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene

1 reference

12 December 2020

Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand

1 reference

12 December 2020

Clinical studies of human papilloma vaccines in cervical cancer

1 reference

12 December 2020

Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer

1 reference

12 December 2020

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine

1 reference

12 December 2020

Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer

1 reference

12 December 2020

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

1 reference

12 December 2020

Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules

1 reference

12 December 2020

Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts

1 reference

12 December 2020

Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts

1 reference

12 December 2020

Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection

1 reference

12 December 2020

Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2

1 reference

12 December 2020

Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice

1 reference

12 December 2020

Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency

1 reference

12 December 2020

Cell-surface display of E7 antigen from human papillomavirus type-16 inLactococcus lactisand inLactobacillus plantarumusing a new cell-wall anchor from lactobacilli

1 reference

12 December 2020